nattokinasa

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• angina [Insufficient Evidence]
• atherosclerosis [Insufficient Evidence]
• cancer [Insufficient Evidence]
• cardiovascular dz [Insufficient Evidence]
• chronic fatigue syndrome [Insufficient Evidence]
• endometriosis [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• hemorrhoids [Insufficient Evidence]
• HTN [Insufficient Evidence]
• hyperlipidemia [Insufficient Evidence]
• impaired glucose tolerance [Insufficient Evidence]
• infertility [Insufficient Evidence]
• peripheral arterial dz [Insufficient Evidence]
• stroke [Insufficient Evidence]
• venous insufficiency [Insufficient Evidence]
• venous thromboembolism [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

atherosclerosis

[Insufficient Evidence]

Dose: 10,800 fibrinolytic units PO qd; Info: used w/ aspirin

HTN

[Insufficient Evidence]

Dose: 2000 fibrinolytic units PO qd; Alt: 30 g extract PO qd

hyperlipidemia

[Insufficient Evidence]

Dose: 10,800 fibrinolytic units PO qd; Info: used w/ aspirin and vitamin K2

impaired glucose tolerance

[Insufficient Evidence]

Dose: 34 fibrinolytic units PO bid

venous insufficiency

[Insufficient Evidence]

Dose: 2000 fibrinolytic units PO qd

venous thromboembolism

[Insufficient Evidence]

Dose: 2000 fibrinolytic units PO qd; Info: start 30 days after tx w/ fondaparinux or enoxaparin